An Illinois federal judge canned a $140 million verdict against AbbVie and ordered a new trial involving its testosterone replacement therapy, AndroGel, after ruling the jury’s findings were contradictory.

The plaintiff, Jeffrey Konrad, claimed AbbVie inappropriately marketed AndroGel, misrepresenting its safety and efficacy for treating age-related hypogonadism and causing him to suffer a heart attack.

Although the jury took AbbVie’s side in October regarding the claim of strict liability, it also found that the company was negligent and falsely represented the safety and effectiveness of AndroGel, ordering the pharmaceutical giant to pay Konrad $140 million in punitive damages.